Citations

Clear

3030 citation(s) found for "Susan, M".

The Effects of Variable Tension Forces on Exoskeletons’ Effectiveness
Kim, Joseph , Norasi, Hamid , Kim, Joseph Y , Stone, Richard , Hallbeck, M. Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | October 31, 2023 | Volume: 67 | Issue: 1 | Pages: 1958-1964

10.1177/21695067231192533 Get It

Exoskeletons are ergonomic devices that can support workers to improve performance and worker safety. This study created an apparatus that simulated a head-and-neck exoskeleton designed for surgeons to test the effects of varying tension forces on muscle activation (splenius capitis, splenius cervices, and erector spinae), body part discomfort, dexterity, cognition, and overall usability of the device. Eight participants were involved in twelve trials over two days and held static postures (looking down at 45° or 90°) for 20 minutes with 10-minute breaks between trials. Six trials utilized tension forces, which were recorded every two minutes and then averaged for each trial. A bivariate regression analysis ( on each metric vs. average tension forces demonstrated that increasing tension forces led to decreased muscle activity of the left splenius capitis, change in general body pain, change in neck discomfort, and the rate of discomfort developing, and improved usability scores.
Determining call-to-entry rate and recruitment barriers in clinical studies for community clinics serving low-income populations: a cohort study
Vaughan, Elizabeth M. , Cardenas, Victor J. , Porterfield, Laura , Delgado, Zuleica Santiago , Samson, Susan L. , Schick, Vanessa , Naik, Aanand D. , Virani, Salim S. , Rifai, Mahmoud Al , Johnston, Craig Allen

Mayo Clinic

BMJ Open | October 28, 2023 | Volume: 13 | Issue: 10 | Pages: e077819

10.1136/bmjopen-2023-077819 | PMID 37898484 Get It

Background Recruitment for clinical studies is challenging. To overcome barriers, investigators have previously established call-to-entry rates to assist in planning. However, rates specific to low-income minority populations are needed to account for additional barriers to enrolment these individuals face. Objective To obtain a call-to-entry rate in a low-income uninsured Hispanic population with chronic disease. Methods We used data from four of our randomised clinical studies to determine the call-to-entry rate for individuals (n=1075) with or at risk for type 2 diabetes: participants needed/potential participants contacted=recruitment rate (yield). Research staff contacted potential participants to enrol in a study that evaluated 6 month diabetes programmes at community clinics from 2015 to 2020. We recorded call-to-entry rates, reasons for declining the study, show rates, and attrition. Results The call-to-entry rate was 14.5%. Forty per cent of potential participants could not be contacted, and 30.6%, 19.1%, and 5.4% responded yes , no , and maybe , respectively. No show percentages were 54% for yes and 91.4% for maybe responders. The majority (61.6%) declined due to inability to attend; reasons to decline included work (43%), eligibility (18%), transportation (10%), out of town (9%), did not think they needed the programme (7%) and other/unknown (14%). Being a physician predicted inability to reach participants (adjusted OR 2.91, 95% CI 1.73 to 4.90). Attrition was 6.8%. Conclusions We described a call-to-entry rate and detailed recruitment data, including reasons to decline the study. This valuable information can assist investigators in study planning and overcoming enrolment barriers in low-income populations. Telehealth-based or strategies that limit transportation needs may increase participant involvement. Trial registration number NCT03394456 .
Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group
Rabin, Karen R. , Chen, Zhiguo , Ji, Lingyun , Kairalla, John A. , Hitzler, Johann , Carroll, Andrew J. , Heerema, Nyla A. , Borowitz, Michael J., Reshmi, Shalini C. , Bhojwani, Deepa , Maloney, Kelly W. , Mattano, Leonard A. , Larsen, Eric , Salzer, Wanda L. , Carroll, William L. , Raetz, Elizabeth A. , Loh, Mignon L. , Angiolillo, Anne , Ji, Lingyun , Hitzler, Johann K , Yang, Jun J.J. , Carroll, Andrew J , Wood, Brent L , Roberts, Kathryn G , Mullighan, Charles G , Harvey, Richard , Willman, Cheryl , Gastier‐Foster, Julie M. , Rheingold, Susan R , Maloney, Kelly W , Mattano, Leonard A , Schore, Reuven J , Burke, Michael J , Winick, Naomi Joan , Raetz, Elizabeth A , Loh, Mignon L , Hunger, Stephen P , Rabin, Karen R , Devidas, Meenakshi , Wood, Brent L. , Roberts, Kathryn G. , Mullighan, Charles G. , Harvey, Richard C. , Chen, I‐Ming , Willman, Cheryl L. , Hunger, Stephen P.

Mayo Clinic

Journal of Clinical Oncology | October 27, 2023 | Volume: 42 | Issue: 2 | Pages: 218-227

10.1200/jco.23.00389 | PMID 37890117 Get It

PURPOSE Patients with Down syndrome (DS) and B-ALL experience increased rates of relapse, toxicity, and death. We report results for patients with DS B-ALL enrolled on Children's Oncology Group trials between 2003 and 2019. METHODS We analyzed data for DS (n = 743) and non-DS (n = 20,067) patients age 1-30 years on four B-ALL standard-risk (SR) and high-risk trials. RESULTS Patients with DS exhibited more frequent minimal residual disease (MRD) ≥0.01% at end induction (30.8% v 21.5%; P < .001). This difference persisted at end consolidation only in National Cancer Institute (NCI) high-risk patients (34.0% v 11.7%; P < .0001). Five-year event-free survival (EFS) and overall survival (OS) were significantly poorer for DS versus non-DS patients overall (EFS, 79.2% ± 1.6% v 87.5% ± 0.3%; P < .0001; OS, 86.8% ± 1.4% v 93.6% ± 0.2%; P < .0001), and within NCI SR and high-risk subgroups. Multivariable Cox regression analysis of the DS cohort for risk factors associated with inferior EFS identified age >10 years, white blood count >50 × 103/μL, and end-induction MRD ≥0.01%, but not cytogenetics or CRLF2 overexpression. Patients with DS demonstrated higher 5-year cumulative incidence of relapse (11.5% ± 1.2% v 9.1% ± 0.2%; P = .0008), death in remission (4.9% ± 0.8% v 1.7% ± 0.1%; P < .0001), and induction death (3.4% v 0.8%; P < .0001). Mucositis, infections, and hyperglycemia were significantly more frequent in all patients with DS, while seizures were more frequent in patients with DS on high-risk trials (4.1% v 1.8%; P = .005). CONCLUSION Patients with DS-ALL exhibit an increased rate of relapse and particularly of treatment-related mortality. Novel, less-toxic therapeutic strategies are needed to improve outcomes.
Using Group Concept Mapping to Explore Medical Education’s Blind Spots
Tackett, Sean , Steinert, Yvonne , Mirabal, Susan , Reed, Darcy A. , Wright, Scott M. , Mirabal, Susan , Wright, Scott M

Mayo Clinic

Teaching and Learning in Medicine | October 27, 2023 | Volume: 37 | Issue: 1 | Pages: 75-85

10.1080/10401334.2023.2274991 | PMID 37886902 Get It

Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia
Bergeman, Auke T. , Lieve, Krystien V.V. , Kallas, Dania , Bos, J. Martijn , Noguer, Ferran Rosés i, Denjoy, Isabelle , Zorio, Esther , Kammeraad, Janneke A.E. , Peltenburg, Puck J. , Tobert, Katie, Aiba, Takeshi , Batra, Anjan S. , Borggrefe, Martin , Cox, Moniek G.P.J. , Dhillon, Santokh , Etheridge, Susan P. , Fischbach, Peter , Franciosi, Sonia , Horie, Minoru , Johnsrude, Christopher L. , Kane, Austin, Krause, Ulrich , Kwok, Sit‐Yee , Ohno, Seiko , Roberts, Jason D. , Robyns, Tomas , Sacher, Frédéric , Semsarian, Christopher , Swan, Heikki, Tavačová, Terézia , Tisma‐Dupanovic, Svjetlana , Tfelt‐Hansen, Jacob , Yap, Sing‐Chien , Till, Janice, Sanatani, Shubhayan , Ackerman, Michael J. , Wilde, Arthur A.M. , Rosés‐Noguer, Ferran , Atallah, Joseph , Drago, Fabrizio , Brugada, Ramón , Borggrefe, Martin , Clur, Sally-Ann B , Cox, Moniek G P J , Davis, Andrew , Dhillon, Santokh , Etheridge, Susan P , Haugaa, Kristina , Horie, Minoru , Johnsrude, Christopher , Krause, Ulrich , LaPage, Martin J , Ohno, Seiko , Probst, Vincent , Roberts, Jason D , Robyns, Tomas , Sacher, Frederic , Semsarian, Christopher , Skinner, Jonathan R , Tavacova, Terezia , Tisma-Dupanovic, Svjetlana , Tfelt-Hansen, Jacob , Yap, Sing-Chien , Kannankeril, Prince J , Leenhardt, Antoine , Sanatani, Shubhayan , Ackerman, Michael J , Wilde, Arthur A M , van der Werf, Christian , Bos, Johan M , Zorio, Esther , Denjoy, Isabelle , Rosés-Noguer, Ferran , Kammeraad, Janneke A E , Lieve, Krystien V , Peltenburg, Puck J , Aiba, Takeshi , Atallah, Joseph , Clur, Sally‐Ann B. , Davis, Andrew M. , Haugaa, Kristina H. , Skinner, Jonathan R. , Kannankeril, Prince J. , Leenhardt, Antoine , Tanck, Michael , Werf, Christian van der , Bergeman, Auke T

Mayo Clinic

Circulation | October 27, 2023 | Volume: 148 | Issue: 25 | Pages: 2029-2037

10.1161/circulationaha.123.064786 | PMID 37886885 Get It

BACKGROUND: In severely affected patients with catecholaminergic polymorphic ventricular tachycardia, beta-blockers are often insufficiently protective. The purpose of this study was to evaluate whether flecainide is associated with a lower incidence of arrhythmic events (AEs) when added to beta-blockers in a large cohort of patients with catecholaminergic polymorphic ventricular tachycardia. METHODS: From 2 international registries, this multicenter case cross-over study included patients with a clinical or genetic diagnosis of catecholaminergic polymorphic ventricular tachycardia in whom flecainide was added to beta-blocker therapy. The study period was defined as the period in which background therapy (ie, beta-blocker type [beta1-selective or nonselective]), left cardiac sympathetic denervation, and implantable cardioverter defibrillator treatment status, remained unchanged within individual patients and was divided into pre-flecainide and on-flecainide periods. The primary end point was AEs, defined as sudden cardiac death, sudden cardiac arrest, appropriate implantable cardioverter defibrillator shock, and arrhythmic syncope. The association of flecainide with AE rates was assessed using a generalized linear mixed model assuming negative binomial distribution and random effects for patients. RESULTS: A total of 247 patients (123 [50%] females; median age at start of flecainide, 18 years [interquartile range, 14–29]; median flecainide dose, 2.2 mg/kg per day [interquartile range, 1.7–3.1]) were included. At baseline, all patients used a beta-blocker, 70 (28%) had an implantable cardioverter defibrillator, and 21 (9%) had a left cardiac sympathetic denervation. During a median pre-flecainide follow-up of 2.1 years (interquartile range, 0.4–7.2), 41 patients (17%) experienced 58 AEs (annual event rate, 5.6%). During a median on-flecainide follow-up of 2.9 years (interquartile range, 1.0–6.0), 23 patients (9%) experienced 38 AEs (annual event rate, 4.0%). There were significantly fewer AEs after initiation of flecainide (incidence rate ratio, 0.55 [95% CI, 0.38–0.83]; P =0.007). Among patients who were symptomatic before diagnosis or during the pre-flecainide period (n=167), flecainide was associated with significantly fewer AEs (incidence rate ratio, 0.49 [95% CI, 0.31–0.77]; P =0.002). Among patients with ≥1 AE on beta-blocker therapy (n=41), adding flecainide was also associated with significantly fewer AEs (incidence rate ratio, 0.25 [95% CI, 0.14–0.45]; P <0.001). CONCLUSIONS: For patients with catecholaminergic polymorphic ventricular tachycardia, adding flecainide to beta-blocker therapy was associated with a lower incidence of AEs in the overall cohort, in symptomatic patients, and particularly in patients with breakthrough AEs while on beta-blocker therapy.
Genomic epidemiology reveals the dominance of Hennepin County in the transmission of SARS-CoV-2 in Minnesota from 2020 to 2022
Scotch, Matthew , Lauer, Kimberly P., Wieben, Eric D. , Cherukuri, Yesesri , Cunningham, Julie M. , Klee, Eric W. , Harrington, Jonathan J. , Lau, Julie S., McDonough, Samantha J., Mutawe, Mark M., Rentmeester, Chad E., Schlicher, Nicole R., White, Valerie T., Schneider, Susan K., Vedell, Peter T. , Wang, Xiong , Yao, Joseph D. , Pritt, Bobbi S. , Lauer, Kimberly, Pritt, Bobbi S , Norgan, Andrew P , O’Horo, John C. , Norgan, Andrew P.

Mayo Clinic

mSphere | October 26, 2023 | Volume: 8 | Issue: 6 | Pages: No page available

10.1128/msphere.00232-23 | PMID 37882516 Get It

ABSTRACT Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had an unprecedented impact on human health and highlights the need for genomic epidemiology studies to increase our understanding of virus evolution and spread and to inform policy decisions. We sequenced viral genomes from over 22,000 patient samples tested at Mayo Clinic Laboratories between 2020 and 2022 and used Bayesian phylodynamics to describe county and regional spread in Minnesota. The earliest calculated introduction into Minnesota was to Hennepin County from a domestic source around 22 January 2020; 6 weeks before the first confirmed case in the state. This led to the virus spreading to Northern Minnesota and, eventually, the rest of the state. International introductions were most abundant in Hennepin (home to the Minneapolis/St. Paul International Airport) totaling 45 (out of 107) over the 2-year period. Southern Minnesota counties were most common for domestic introductions, with 19 (out of 64), potentially driven by bordering states such as Iowa and Wisconsin as well as Illinois, which is nearby. Hennepin also was, by far, the most dominant source of in-state transmissions to other Minnesota locations ( n = 772) over the 2-year period. We also analyzed the diversity of the location source of SARS-CoV-2 viruses in each county and noted the timing of state-wide policies as well as trends in clinical cases. Neither the number of clinical cases nor the major policy decisions, such as the end of the lockdown period in 2020 or the end of all restrictions in 2021, appeared to have an impact on virus diversity across each individual county. IMPORTANCE We analyzed over 22,000 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomes of patient samples tested at Mayo Clinic Laboratories during a 2-year period in the COVID-19 pandemic, which included Alpha, Delta, and Omicron variants of concern to examine the roles and relationships of Minnesota virus transmission. We found that Hennepin County, the most populous county, drove the transmission of SARS-CoV-2 viruses in the state after including the formation of earlier clades including 20A, 20C, and 20G, as well as variants of concern Alpha and Delta. We also found that Hennepin County was the source for most of the county-to-county introductions after an initial predicted introduction with the virus in early 2020 from an international source, while other counties acted as transmission “sinks.” In addition, major policies, such as the end of the lockdown period in 2020 or the end of all restrictions in 2021, did not appear to have an impact on virus diversity across individual counties.
Strategies for Data Ethics Governance: Elevating Patient and Community Perspectives
Stroud, Austin M. , Wise, Journey L. , Curtis, Susan , McGowan, Michelle L. , Curtis, Susan H

Mayo Clinic

The American Journal of Bioethics | October 25, 2023 | Volume: 23 | Issue: 11 | Pages: 48-50

10.1080/15265161.2023.2256277 | PMID 37879006 Get It

Optimizing schools of cytology: Discussions from the 2022 ASC/IAC Cytology Education Symposium, North American Strategies, and European Symbiosis
LeBlanc, Jenna B., Smith, Michele A., McNair, Sean A., Hansing, Kara L. , Bammert, Catherine E., Russell, Donna , Howell, Joshua M. , Alperstein, Susan, Lennen, Kelly, Paradis, Veronika Anic, Zuylen‐Manders, Lia van, Liikanen, Eeva , Freund, Gregory G. , Davey, Diane D. , Goulart, Robert A. , Yuil‐Valdes, Ana, Brainard, Jennifer , Hitchens, Sandra W., Donnelly, Amber , Srebotnik-Kirbis, Irena , Sturgis, Charles D. , Vielh, Philippe R.

Mayo Clinic

Cytopathology | October 25, 2023 | Volume: 35 | Issue: 1 | Pages: 2-6

10.1111/cyt.13314 | PMID 37877689 Get It

AbstractThis report highlights information and outcomes from the November 2022 ASC/IAC joint Cytology Education Symposium, an annual conference organized by the Cytology Programs Review Committee. The manuscript provides information on shared educational opportunities and practices for cytology students and other learners in anatomic pathology, discusses recruitment strategies for schools of cytology, conveys teaching resources, introduces perspectives on virtual microscopy and online learning, and transmits information about wellness of students in schools of cytology.
Left ventricle outflow tract obstruction after transcatheter mitral valve replacement with a transatrial approach
Farina, Juan M. , Jokerst, Clinton, Wilansky, Susan , Arsanjani, Reza , Arsanjani, Reza , Farina, Juan M , Sell‐Dottin, Kristen

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | October 23, 2023 | Volume: 25 | Issue: 3 | Pages: e108-e108

10.1093/ehjci/jead279 | PMID 37875138 Get It

Artificial intelligence-enabled operating room data analysis: Current and future prospects for enhancing surgical safety
Tetteh, Emmanuel , Wang, Tianke, Norasi, Hamid , Kim, Joseph , Tetteh, Emmanuel , Kim, Joseph Y , Wang, Tianke , Cleary, Sean P. , Hallbeck, M. Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | October 21, 2023 | Volume: 67 | Issue: 1 | Pages: 2079-2081

10.1177/21695067231192661 Get It

Despite advances in medical technology, intraoperative adverse events (IAE) continue to occur in hospital’s complex systems. Current approaches to understanding and mitigating IAEs rely on retrospective data analyses to recognize the series of events leading to an IAE. This paper discusses current challenges and highlights the potential of the Operating Room Blackbox (ORBB) system use to enhance patient safety.